麻豆传媒

Brett Wingeier, Ph.D., is co-founder and chief executive officer of Magnus Medical and a member of its Board of Directors. He brings over 20 years of experience in the development and commercialization of advanced neurotechnology. Most recently, he was a co-founder of Halo Neuroscience, where he was chief technology officer and later assumed the additional role of CEO. During his tenure at Halo, he raised $26 million over seven years to commercialize non-invasive electrical brain stimulation across consumer and medical applications. He was also the architect of Halo Sport, the world鈥檚 first consumer neurostimulation headset for movement training, as well as the company鈥檚 next-generation products, which remain under development for cognitive and psychiatric health. As CTO, he built and supervised hardware and software development teams, led Halo鈥檚 applied neuroscience research program, led manufacturing operations in the U.S. and Asia, and managed IP and regulatory affairs. As CEO, he additionally supervised clinical affairs, distribution, e-commerce, direct-to-consumer sales, partnerships, marketing, and customer support for Halo鈥檚 portfolio of products. 

Before co-founding Halo, Dr. Wingeier was one of the first employees at NeuroPace, where he co-developed the world鈥檚 first responsive neurostimulator for epilepsy鈥攃alled the RNS System鈥攚hich received PMA approval from the U.S. Food & Drug Administration (FDA) in 2013. At NeuroPace, he was the principal biomedical engineer responsible for firmware engineering, clinical science, biostatistics, and product management. Today, the RNS System is an accepted treatment for intractable epilepsy, with over 2,000 implants and 82% seizure frequency reduction. In parallel, he was instrumental in the development and clinical trial of Autonomic Technologies鈥� Pulsante implant, which attained CE Mark certification to treat cluster headaches in 2012, and migraine headaches in 2017. 

Dr. Wingeier received a Bachelor of Science in Biomedical Engineering and his Ph.D. in Biomedical Engineering, both from Tulane University. He has completed additional studies at Swinburne University鈥檚 Brain Science Institute and at Stanford Biodesign. Dr. Wingeier is a registered patent agent, a prolific inventor with over 60 issued U.S. patents, and a member of the IEEE Working Group on Neuroethics.

, is a psychiatrist and internationally recognized expert in treating severe psychiatric disorders with magnetic brain stimulation, also known as transcranial magnetic stimulation (TMS).
He uses TMS to help patients with treatment-resistant depression and is the director of UC San Diego Health's Interventional Psychiatry Clinic, the region's largest clinic dedicated to treating severe depression with brain stimulation approaches.
As chair of the Department of Psychiatry at UC San Diego School of Medicine, Daskalakis is leading research on the use of TMS in people with treatment-resistant schizophrenia, suicidal thoughts and obsessive compulsive disorders. Treatment-resistant diseases are those that may not be resolved adequately through traditional medications and talk therapy alone.
Daskalakis says the most rewarding aspect of his clinical practice is being able to help people who have not found relief through conventional approaches. This is why his research focuses on novel approaches such as brain stimulation for treating mental health conditions.